

Total Hip Replacement: Optimising Outcomes for Patients with Co-Morbidities


Prof Joseph M Queally
Consultant Orthopaedic Surgeon
Associate Professor Trinity College Dublin

Learning Outcomes


- Contemporary success rate of total hip replacement
- Effect of-comorbidities on outcomes
- Optimising outcomes in these patients

How Successful is Contemporary Total Hip Replacement?


Measuring Success after Total Hip Replacement....



Measuring Success after Total Hip Replacement....



Measuring Success after Total Hip Replacement....



Measuring Success after Total Hip Replacement....

Lancet 2019; 393: 647-54

How long does a hip replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up

Jonathan T Evans, Jonathan P Evans, Robert W Walker, Ashley W Blom, Michael R Whitehouse, Adrian Sayers**

Systematic review including case series and national joint registry data

228,888 hips reporting on 15 year survival or above

ODEP standard: 95% at 10 years

Current Evidence




Figure 4: Comparison of pooled survival estimates from case series and registry reports at 15 years, 20 years, and 25 years

15 years.... 85%

20 years.... 75%

25 years.... 58%

Current Evidence - Worldwide

Over half of patients who have a total hip replacement can expect their hip implant to last 25 years

- Avg age 67
- 55% Women
- 88% for Osteoarthritis

Current Evidence - Ireland

2010 – 2019: 75,399 THR and TKR (PUBLIC HOSPITALS ONLY)

Avg age: 70 in 2019 (up from 67)

93% of patients aged 50 or above

50% split male/female

increasing numbers

5590 in 2019

12325 in 2051 (predicted)

A study of population trends and future projections for the hip and knee arthroplasty service in the Republic of Ireland

Katie St John^{a,*}, Andrew Hughes^{b,ip}, Joseph Queally^{b,c}

^a *Bons Secours Hospital, Renmore, Galway, Ireland*

^b *Department of Orthopaedic Surgery, St James's Hospital, James Street, D08 NHY1, Dublin, Ireland*

^c *School of Medicine, Trinity College Dublin, Dublin, Ireland*

Increasing Numbers, Older Patients and more Co-Morbidities


How can we optimize outcomes in a more complex patient population?

- Patient selection
- Modifiable risk factors
- Perioperative planning
- Patient Education/Consent

Increasing Numbers, Older Patients and more Co-Morbidities



Haemophilia



Biologics in Rheum: **TNF Blockers**

Etanercept	• Enbrel, Bimzys, Erelzi
Adalimumab	• Humira, Hyrimoz, Hulo, Hadlima, Yuflyma, Idacio, Abridada, Amgevta, Simlandi, Adalimumab
Certolizumab	• Cimzia
Golimumab	• Simponi
Infliximab	• Remicade, Avsola, Inflectra, Refflixo

Why do Hip Replacements Fail?

Why do Hip Replacements Fail?



Loosening

Why do Hip Replacements Fail?



Loosening



Fracture

Why do Hip Replacements Fail?



Loosening



Fracture



Dislocation

Why do Hip Replacements Fail?



Loosening



Fracture



Dislocation



Infection

What is the Effect of Common Co-Morbidities ?

Obesity

Diabetes

Kidney Disease

Malnutrition

Obesity



The Effect of Obesity on Having a Hip Replacement

Osteoarthritis and Cartilage



Osteoarthritis and Cartilage 28 (2020) 31–44

Greater risks of complications, infections, and revisions in the obese versus non-obese total hip arthroplasty population of 2,190,824 patients: a meta-analysis and systematic review

J.R. Onggo †*, J.D. Onggo †, R. de Steiger ‡, R. Hau †§

Systematic review/meta-analysis looking at

non-obese (BMI < 30)

obese (BMI >30)

morbidly obese (BMI >40)

2,190,824 patients

The Effect of Obesity on Having a Hip Replacement

Increased risk of complications	Obese (>30)	Morbidly Obese > 40
all complications	1.53	2.68
revisions	1.44	2.17 (3-8%)
infection	2.71	3.69 (2% – 4 %)
dislocation	1.72	2.12

Infection... major problem for patient, doctors, healthcare system

The Effect of Obesity on Having a Hip Replacement

Obesity and morbid obesity (BMI > 40) in particular significantly increases the risk of complications after total hip replacement

? Proceed with hip replacement v ?delay/trial of weight loss to reduce BMI/risks

Optimising Outcomes in Obese Patients

Patients must be informed of risks and be given opportunity to reduce BMI, particularly if BMI > 40

Signpost or refer to GP or weight loss program

? Role for GLP 1 agonists

Optimising Outcomes in Obese Patients

Retrospective study comparing Semaglutide versus placebo, complications after total hip and knee replacement

7 051 versus 34, 524

Decreased risk of

periprosthetic joint infection (2.1% versus 3.0 %)

90 day readmission (7.5 versus 9.4%)

Semaglutide Use Prior to Total Hip Arthroplasty Results in Fewer Postoperative Prosthetic Joint Infections and Readmissions

[Matthew L. Magruder, MD^a](#) · [Michael J. Miskiewicz, BS^a](#) · [Ariel N. Rodriguez, MD^a](#) · [Michael A. Mont, MD^c](#)

THE JOURNAL OF
ARTHROPLASTY

Step 9 Trial

Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis

Authors: Henning Bliddal, M.D., Harold Bays, M.D., Sébastien Czernichow, M.D., Ph.D. , Joanna Uddén Hemmingsson, M.D., Ph.D., Jøran Hjelmæsæth, M.D., Ph.D., Thomas Hoffmann Morville, M.D., Ph.D., Anna Koroleva, M.D.,  ⁺⁵, for the STEP 9 Study Group* [Author Info & Affiliations](#)

Published October 30, 2024 | N Engl J Med 2024;391:1573-1583 | DOI: 10.1056/NEJMoa2403664

[VOL. 391 NO. 17](#) | [Copyright © 2024](#)

Semaglutide v placebo (diet and exercise guidance only)

407 patients, 68 weeks


WT loss 13.7% versus 3.2%

Optimising Outcomes in Obese Patients

WT loss 13.7% versus 3.2%

Significantly improved

- Pain
- Functional scores
 - Womac knee score (41.7 v 27.5 change in score)
 - SF-12 (12 v 6.5 change in score)



Beacon Obesity and Bariatric Service

Beacon Hospital Obesity Care Pathway

Level 3 & 4 Service – Irish Obesity Model of Care

GP / Consultant Referral

(BMI ≥ 30 or ≥ 27 with co-morbidities)



Specialist MDT Assessment



LEVEL 3: Medical Obesity Care

- Dietetic medical nutrition therapy
- Behaviour change support
- Obesity pharmacotherapy (if indicated)
- Metabolic risk optimisation



LEVEL 4: Bariatric Surgery Pathway

- Structured preparation
- Bariatric surgery
- Long-term follow-up

Patients may move up or down the pathway depending on clinical need.

Mr. William Robb Consultant Upper GI Surgeon – Oesophago-Gastric Cancer, Bariatric and General Surgeon



Mr. Waqas Butt Consultant General, Upper GI & Bariatric Surgeon



Dr. Matilde Mijares Zamuner, Consultant Endocrinologist



Jessica Mellotte Clinical Specialist Dietitian Obesity and Bariatric Surgery



What will the Service offer/ How to refer?

- Specialist medical & surgical obesity care.
- Safe prescribing, support and monitoring of obesity pharmacotherapy.
- Pre- and post-bariatric surgery pathways.
- Identification of nutritional risk, behavioural and lifestyle modification and exercise therapy.

When to Refer

- BMI 30
- Complex obesity with related co-morbidities.
- Patients who wish to be considered for pharmacotherapy or bariatric surgery.
- Excess or dysfunctional adipose tissue impacting function, QOL, pain, or metabolic health.

Referrals can be sent to:

 obesityandbariatrics@beaconhospital.ie

GP's can refer directly to the service via health link

Diabetes



The Effect of Diabetes on Having a Hip Replacement

The impact of glycaemic control and diabetes mellitus on perioperative outcomes after total joint arthroplasty
Milford MH, Viens N, Cook C, Vail T, Bolognesi M



2009 Jul;91(7):1621-9

Retrospective review looking at complications in diabetic patients who had a total joint replacement

no diabetes 920,555

controlled diabetes 105485

uncontrolled diabetes 3973

The Effect of Diabetes on Having a Hip Replacement

Increased risk of complications in uncontrolled diabetes versus controlled diabetes

CVA 3.42 (odds ratios)

UTI 1.47

Transfusion 1.19

Infection 2.28 (0.7 % versus 2.4%)

Death 3.23

Increased length of stay (1-2 days)

Optimising Outcomes in Diabetic Patients

Preoperative control important..... HBA1c should be < 7% (preassessment clinic gatekeeping)

Perioperative control (endocrine team input)

Manage other co-morbidities typical with diabetes

Chronic Kidney Disease



Effect of chronic kidney disease on outcomes of total joint arthroplasty: a meta-analysis

Chang-Wan Kim^{1†}, Hyun-Jung Kim^{2†}, Chang-Rack Lee^{1*} , Lih Wang³ and Seung Joon Rhee⁴

Meta-analysis looking at looking at complications after total joint replacement in patients with and without chronic kidney disease

Prevalence 8 – 16%

27 studies, 100,000 patients

The Effect of Diabetes on Having a Hip Replacement

Increased risk of complications in patients with chronic kidney

Mortality	1.89,	(higher if on dialysis 4.2)
Infection	1.37	(no difference if on dialysis)
Revision risk	2.15	(increased only if on dialysis)

Optimising Outcomes in Chronic Kidney Disease Patients

Risk stratification

Optimising renal function before, during and after surgery

Dialysis available in Beacon

Malnutrition

The Effect of Malnutrition on having a Hip Replacement

Preoperative Malnutrition Negatively Correlates With Postoperative Wound Complications and Infection After Total Joint Arthroplasty:

A Systematic Review and Meta-Analysis

Gu A, Malahias A, Strigelli V, Nocon A, Sculco TP, Sculco K
J of Arthroplasty 2018

Meta-analysis looking at looking at complications after total joint replacement in patients with malnutrition.

20 studies that investigated serological malnutrition

low albumin <3.5 g/dl

low total lymphocyte count <1500 cells/mm³

prevalence of 5- 30%

The Effect of Malnutrition on having a Hip Replacement

Increased risk of complications in patients with malnutrition

Delayed wound healing	2.176
Wound infection	up to 5

The Effect of Malnutrition on having a Hip Replacement

If malnutrition suspected, assess with albumin/total lymphocyte count

Delay surgery until albumin $>3.5\text{g/dl}$, TLC > 1500

Summary

Total Hip Replacement is generally a successful procedure

95% satisfaction

60% can expect their hip replacements to last 25 years

Older patients more medical co-morbidities

Recognising co-morbidities, advising re risks and optimizing care pre and perioperatively critical to achieving best outcomes

BMI >40 Consider GLP1 agonist treatment as part of a program

HBA1C < 7

A large, stylized, light blue 'S' shape is positioned on the left side of the slide, partially overlapping the main text area. The background is a solid dark blue.

Thank you